Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

Phase 3

• Conditions: Renal Cell Carcinoma
• Interventions: Other: Endurance exercise

• Registration Number: NCT00869011
• Lead Sponsor: Charite University, Berlin, Germany

Brief Summary

In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-03-23
• Study First Submitted QC: 2009-03-24
• Study First Posted: 2009-03-25
• Status Verified: 2009-12
• Study Start: 2009-12
• Last Update Submitted: 2009-12-21
• Last Update Posted: 2009-12-23
• Primary Completion: 2011-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• 18 to 75 years
• Understanding of written German
• Treatment with Sunitinib
• Ability to walk

Exclusion Criteria

• Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise
• BMI < 18 or > 30

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Endurance exercise	Exercise

Primary Outcome Measures

Name	Time	Method
Fatigue	12 weeks

Secondary Outcome Measures

Name	Time	Method
VO2max	12 weeks
Depression score	12 weeks
Systolic and diastolic blood pressure (24 h)	12 weeks

Trial Locations

Locations (1)

Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30; 🇩🇪 Berlin, Germany